Literature DB >> 17657833

Adjuvant therapies for colorectal cancer.

Suzanne Kosmider1, Lara Lipton.   

Abstract

The management of colon and rectal cancer has changed dramatically over the last 25 years. The use of adjuvant therapies has become standard practice in locally advanced (stage III and selected stage II) colorectal cancer. Improved surgical techniques, chemotherapeutics and radiotherapy are resulting in higher cure rates and the development of agents targeting proliferative and angiogenic pathways offer further promise. Here we explore risk factors for local and distant recurrence after resection of colon and rectal cancer, and the role of adjuvant treatments. Discussion will focus on the evidence base for adjuvant therapies utilised in colorectal cancer, and the treatment of sub-groups such as the elderly and stage II disease. The role of adjuvant radiotherapy in rectal cancer in reduction of recurrence will be explored and the role and optimal methods for surveillance post-curative resection with or without adjuvant therapy will also be addressed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657833      PMCID: PMC4611211          DOI: 10.3748/wjg.v13.i28.3799

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  55 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Preoperative assessment of local tumor extent in advanced rectal cancer: CT or high-resolution MRI?

Authors:  R G Beets-Tan; G L Beets; A C Borstlap; T K Oei; T M Teune; M F von Meyenfeldt; J M van Engelshoven
Journal:  Abdom Imaging       Date:  2000 Sep-Oct

3.  Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.

Authors:  L Påhlman; B Glimelius
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

4.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

5.  Dihydropyrimidine dehydrogenase deficiency in an Indian population.

Authors:  Muhammad Wasif Saif; Lori Mattison; Tom Carollo; Hany Ezzeldin; Robert B Diasio
Journal:  Cancer Chemother Pharmacol       Date:  2006-01-19       Impact factor: 3.333

Review 6.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

Authors:  C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

7.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.

Authors:  P C Simmonds
Journal:  BMJ       Date:  2000-09-02

8.  Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project.

Authors:  A L Martling; T Holm; L E Rutqvist; B J Moran; R J Heald; B Cedemark
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

Review 9.  Improving chemoradiotherapy in rectal cancer.

Authors:  R Glynne-Jones; J Debus
Journal:  Oncologist       Date:  2001

Review 10.  Preoperative staging of rectal cancer.

Authors:  H Kwok; I P Bissett; G L Hill
Journal:  Int J Colorectal Dis       Date:  2000-02       Impact factor: 2.571

View more
  9 in total

Review 1.  Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.

Authors:  Satya Narayan; Ritika Sharma
Journal:  Life Sci       Date:  2015-09-01       Impact factor: 5.037

2.  The physical activity of colorectal cancer survivors during chemotherapy : Based on the theory of planned behavior.

Authors:  Yinan Bao; Si Chen; Ruxin Jiang; Yuewei Li; Lei Chen; Feng Li; Jiandong Tai
Journal:  Support Care Cancer       Date:  2019-06-01       Impact factor: 3.603

3.  A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.

Authors:  Yan Zhang; Junli Ma; Sai Zhang; Ganlu Deng; Xiaoling Wu; Jingxuan He; Haiping Pei; Hong Shen; Shan Zeng
Journal:  Int J Colorectal Dis       Date:  2015-06-09       Impact factor: 2.571

4.  Ribosomal protein S27-like in colorectal cancer: a candidate for predicting prognoses.

Authors:  Chi-Jung Huang; Shung-Haur Yang; Chia-Long Lee; Yu-Che Cheng; Szu-Yun Tai; Chih-Cheng Chien
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

5.  NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.

Authors:  Satya Narayan; Aruna S Jaiswal; Ritika Sharma; Akbar Nawab; Lizette Vila Duckworth; Brian K Law; Maria Zajac-Kaye; Thomas J George; Jay Sharma; Arun K Sharma; Robert A Hromas
Journal:  Oncotarget       Date:  2017-08-01

6.  Validation of miRNA prognostic significance in stage II colorectal cancer: A protocol for systematic review and meta-analysis of observational clinical studies.

Authors:  Shanthi Sabarimurugan; Chellan Kumarasamy; Madhav Madurantakam Royam; Karthik Lakhotiya; Gothandam Kodiveri Muthukaliannan; Suja Ramalingam; Rama Jayaraj
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 7.  Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence.

Authors:  Ulrich Nitsche; Christian Stöss; Helmut Friess
Journal:  Gastrointest Tumors       Date:  2017-08-31

8.  Evidence-based treatment of patients with rectal cancer.

Authors:  Qiang Zhang; Jie Yang; Qun Qian
Journal:  Oncol Lett       Date:  2016-01-12       Impact factor: 2.967

9.  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.

Authors:  Satya Narayan; Srinivasa Ramisetti; Aruna S Jaiswal; Brian K Law; Ashona Singh-Pillay; Parvesh Singh; Shantu Amin; Arun K Sharma
Journal:  Eur J Med Chem       Date:  2018-10-23       Impact factor: 6.514

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.